長盈精密(300115.SZ):將第二期員工持股計劃存續期再延長24個月
格隆匯2月28日丨長盈精密(300115.SZ)公佈,基於目前證券市場的情況,綜合考慮公司實際發展狀況,為切實發揮員工持股計劃實施的目的和激勵作用,經第二期員工持股計劃持有人會議及公司第五屆董事會第二十一次會議審議,同意將公司第二期員工持股計劃存續期再延長24個月,即延長至2024年4月27日。此次員工持股計劃可以在存續期內出售股票,若員工持股計劃所持有的公司股票在存續期內全部出售,員工持股計劃可提前終止。
截至公吿日,公司第二期員工持股計劃持有公司股票2564.7841萬股(包括2020年度利潤分配資本公積金轉增股本的部分),佔公司總股本的2.14%。公司第二期員工持股計劃未出售任何股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.